BioSpace News Archive

Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that it plans to release first quarter 2022 financial and operating results prior to market open on Thursday, May 12th, 2022.

ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that all five clinical study sites in Taiwan participating in the Phase II, part 2 clinical study of the company’s ADHD medicine have completed their site initiation visits (SIV).

AVEO Oncology today announced that it will report first quarter 2022 financial results on Thursday, May 5, 2022.

Alimera Sciences, Inc. announced that ILUVIEN® will be highlighted in various scientific abstracts at the annual Association for Research in Vision and Ophthalmology conference being held in Denver, Colorado from May 1-4 and virtually May 11-12, 2022.

T2 Biosystems, Inc. announced today the formation of its Scientific Advisory Board (SAB).

Cryoport, Inc. (Nasdaq: CYRX) (“Cryoport” or the “Company”), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that the Company will report financial results for the three months period ended March 31, 2022 (first quarter 2022) on Thursday, May 5, 2022 after U.S. markets close.

AmerisourceBergen, a global healthcare company, announces a program designed to help hospitals and health systems launch or optimize home infusion service lines.

Iterative Scopes, a pioneer in precision medicine technologies for gastroenterology, announced today that it has acquired Clinical Research Strategy Group, LLC and Precision Research (CRSG/Precision), two clinical trial optimization companies focused on streamlining and accelerating the drug development process for inflammatory bowel disease (IBD).

Clarus Therapeutics Holdings, Inc. today announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for claims that cover its oral testosterone replacement product, JATENZO (testosterone undecanoate).

Scilex Holding Company, a nearly 100% majority-owned subsidiary of Sorrento Therapeutics, Inc., announced that Elizabeth Czerepak will join the company as Executive Vice President, Chief Financial Officer and Chief Business Officer, effective May 18, 2022.